EUVIMEDEUVIMED entdecken
Crossref

Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation

So-Eun Son, Dong-Soon Im

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von So-Eun Son und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Psoriasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As angiotensin II is associated with inflammation, type I angiotensin II receptor blockers (ARBs) exibit anti-inflammatory effects in patients with hypertension as well as inflammatory disease animal models including arthritis models. The present study aimed to investigate whether ARBs exert anti-inflammatory effects in vivo in skin disorders. We tested effects of ARBs on 1-chloro-2,4-dinitrobenzene(CDNB)-induced atopic dermatitis-like and imiquimod-induced psoriasis-like skin models. CDNB-induced atopic dermatitis-like skin lesions were suppressed by administration of candesartan or telmisartan. The suppressive effect of telmisartan was blocked by the presence of GW9662, a selective PPARγ inhibitor, but not that of candesartan. Both ARBs suppressed increases in pro-inflammatory cytokine (IL-4, IL-13, IFN-γ, and IL-17A) levels, and GW9662 inhibited telmisartan-induced suppression but not candesartan. Candesartan significantly inhibited in vitro differentiation of naïve T cells into Th17 cells to a greater extent than telmisartan. In the imiquimod-induced psoriasis model, whose primary etiology is activation of IL-23/IL-17 axis, candesartan significantly suppressed psoriasis-like skin lesions and Th17 cell populations in both lymph nodes and spleens to a greater extent than telmisartan. Overall, certain ARBs may have anti-inflammatory effects in skin diseases. Candesartan may have therapeutic implications in inflammatory skin disorders by suppressing Th17 differentiation, while telmisartan might have therapeutic potential by activating PPARγ.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicPsoriasisAnimalsHumansTelmisartanTh17 CellsAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsPPAR gammaImiquimodBenzoatesAngiotensin-Converting Enzyme InhibitorsSkinCell DifferentiationAnti-Inflammatory AgentsBenzimidazolesBiphenyl CompoundsTetrazolesAnilides

Stichwörter der Autor:innen

ARBAtopyCandesartanDermatitisPsoriasisTelmisartan

Substanzen

TelmisartanAngiotensin II Type 1 Receptor BlockersAngiotensin Receptor AntagonistsPPAR gammaImiquimodBenzoatesAngiotensin-Converting Enzyme InhibitorsAnti-Inflammatory AgentscandesartanBenzimidazoles

Autor:innen und Institutionen

  • Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea.
  • Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea; Department of Fundamental Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seou…

Förderung

  • National Research Foundation of Korea
  • Ministry of Science, ICT and Future Planning

Zitieren

APA

Son, S. E., & Im, D. S. (2023). Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110995

Vancouver

Son SE, Im DS. Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110995

BibTeX
@article{Son2023,
  author = {Son, So-Eun and Im, Dong-Soon},
  title = {Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110995}
}
Kostenlos starten →